For CKD Stage 3B, both Farxiga (dapagliflozin) and Jardiance (empagliflozin) are appropriate first-line SGLT2 inhibitors with comparable efficacy, though recent observational data suggest empagliflozin may have a slight edge in preventing progression to end-stage kidney disease.
Guideline Framework
Current KDIGO guidelines strongly recommend SGLT2 inhibitors as first-line therapy for kidney and heart protection in patients with eGFR ≥20 mL/min/1.73 m² 1, 2. Both dapagliflozin and empagliflozin have proven kidney and cardiovascular benefits and should be prioritized over other SGLT2 inhibitors 1. The guidelines emphasize that SGLT2 inhibitors should be initiated when eGFR is ≥20 mL/min/1.73 m² and continued as tolerated until dialysis or transplantation 2.
For your patient with CKD Stage 3B (eGFR 30-44 mL/min/1.73 m²), both agents are FDA-approved and guideline-recommended 3.
Direct Comparative Evidence
Recent Observational Studies Show Divergent Findings:
Empagliflozin may have an advantage for preventing ESKD progression:
- A 2026 propensity-matched study of 53,774 Stage 3 CKD patients found empagliflozin was associated with lower risk of Stage 5 CKD or ESKD (7.7% vs. 9.0%; HR 0.84,95% CI 0.79-0.89) over ~970 days compared to dapagliflozin 4
- Another 2026 study found dapagliflozin users had a 28% higher risk of ESKD (HR 1.28,95% CI 1.11-1.48) compared to empagliflozin in advanced CKD patients 5
However, outcomes were otherwise comparable:
- Major adverse kidney events (MAKE), major adverse cardiovascular events (MACE), and all-cause mortality showed no significant differences between the two agents 5
- A 2026 network meta-analysis found dapagliflozin 10 mg showed the greatest efficacy for composite renal outcomes (OR 0.55,95% CI 0.42-0.72) among all SGLT2 inhibitors, though this was compared to placebo, not head-to-head 6
Clinical Decision Algorithm
Choose Empagliflozin if:
- Primary concern is preventing progression to dialysis/ESKD
- Patient has diabetes (better cost-effectiveness in diabetic patients) 7
- Reducing albuminuria is a priority (canagliflozin superior, but empagliflozin better than dapagliflozin) 6
Choose Dapagliflozin if:
- Patient does not have diabetes (better cost-effectiveness in non-diabetic CKD) 7
- Primary concern is cardiovascular death prevention (lower cost-per-outcome for CVD prevention) 7
- Patient is already on dapagliflozin with good tolerance
Either agent is appropriate if:
- Preventing heart failure hospitalization is the primary goal
- Patient has no strong preference
- Cost and formulary considerations are equivalent
Practical Implementation
Dosing for CKD Stage 3B:
- Dapagliflozin: 10 mg once daily 3
- Empagliflozin: Standard dosing applies (typically 10 mg, can increase to 25 mg)
Expected initial effects:
- Anticipate a reversible eGFR decline of 3-5 mL/min/1.73 m² in the first 4 weeks 1
- This "eGFR dip" is expected and should not prompt discontinuation
- GFR typically stabilizes during ongoing therapy 1
Continue therapy even if eGFR declines below 20 mL/min/1.73 m² until dialysis is initiated 1, 2
Critical Caveats
The observational studies showing empagliflozin superiority for ESKD prevention have important limitations:
- Residual confounding cannot be excluded despite propensity matching 5
- These are retrospective analyses, not randomized controlled trials
- The absolute difference in ESKD risk was modest (1.3% over ~2.5 years) 4
Both agents require the same risk mitigation strategies:
- Assess volume status before initiation; reduce diuretics if hypovolemia risk 1
- Counsel on genital hygiene to prevent mycotic infections 1
- Implement sick day rules (hold during acute illness with vomiting/diarrhea) 1
- Monitor for ketoacidosis risk, especially if patient has diabetes 1
Bottom Line
In the absence of definitive head-to-head randomized trials, empagliflozin appears to have a modest advantage for preventing progression to ESKD in Stage 3B CKD based on the most recent 2026 observational data 5, 4. However, both agents provide substantial kidney and cardiovascular protection compared to no SGLT2 inhibitor therapy. The choice can reasonably be guided by diabetes status (empagliflozin if diabetic, dapagliflozin if non-diabetic), formulary considerations, and whether preventing dialysis versus cardiovascular death is the higher priority.